N@N

CUR, EMB, SVA, FVE, CNDA, REXX Are Seasonally Ripe To Go Down In the Next Five Weeks

October 17, 2016 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring the Seasonality of Neuralstem Inc. (NASDAQ:CUR), iShares JPMorgan USD Emerging Markets Bond Fund (NYSE:EMB), Sinovac Biotech, Ltd. (NASDAQ:SVA), Five Star Quality Care Inc. (NASDAQ:FVE), INDEXIQ ETF TRIQ CANADA SMALL CAP ETF (NYSE:CNDA), Rex Energy Corporation (NASDAQ:REXX) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. buyins.net is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

The following stocks are expected to go Down:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  CUR     Neuralstem Inc.                  -6.39%           88.89% (8 of 9)      Thursday, October 20th 2016
  EMB     iShares JPMorgan USD Emerging Markets Bond Fund  -1.58%           87.50% (7 of 8)      Monday, November 21st 2016
  SVA     Sinovac Biotech, Ltd.            -6.50%           84.62% (11 of 13)    Tuesday, October 25th 2016
  FVE     Five Star Quality Care Inc.      -4.23%           85.71% (12 of 14)    Thursday, October 20th 2016
  CNDA    INDEXIQ ETF TRIQ CANADA SMALL CAP ETF  -2.75%           66.67% (4 of 6)      Tuesday, October 18th 2016
  REXX    Rex Energy Corporation           -7.68%           88.89% (8 of 9)      Monday, October 24th 2016

Neuralstem Inc. (NASDAQ:CUR) - Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The company s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI 566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. The company was founded in 1996 and is headquartered in Germantown, Maryland..

iShares JPMorgan USD Emerging Markets Bond Fund (NYSE:EMB) - iShares Trust.

Sinovac Biotech, Ltd. (NASDAQ:SVA) - Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against hepatitis A, hepatitis B, seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; and Split viron pandemic influenza vaccine. The company also develops the EV71 vaccine, which has completed Phase III clinical trial. In addition, it has completed pre-clinical studies for varicella, sabin inactivated polio, and hepatitis A and B vaccines; and focuses on commencing clinical trials for pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, and rubella vaccine. The company has a collaboration agreement with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China..

Five Star Quality Care Inc. (NASDAQ:FVE) - Five Star Quality Care, Inc. operates and manages senior living communities in the United States. The company s senior living communities comprise independent living communities, assisted living communities, and skilled nursing facilities (SNFs). It offers nursing and healthcare services. As of December 31, 2015, the company operated 274 senior living communities consisting of 31,417 living units comprising 243 primarily independent and assisted living communities with 28,610 living units, and 31 SNFs with 2,807 living units located in 32 states. Five Star Quality Care, Inc. was founded in 2000 and is based in Newton, Massachusetts..

INDEXIQ ETF TRIQ CANADA SMALL CAP ETF (NYSE:CNDA) - CONCORDIA CORP.

Rex Energy Corporation (NASDAQ:REXX) - Rex Energy Corporation operates as an independent oil, natural gas liquid, and natural gas company in the Appalachian and Illinois basins in the United States. The company focuses on the Marcellus Shale, Utica Shale, and Burkett Shale drilling and exploration activities in the Appalachian Basin, as well as on developmental oil drilling on its properties in the Illinois Basins. As of December 31, 2015, it had estimated proved reserves of 680.4 billion cubic feet equivalent; and owned interests in approximately 1,819 oil and natural gas wells. Rex Energy Corporation was founded in 2007 and is headquartered in State College, Pennsylvania..

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---